ProCE Banner Activity

ATLAS-2M: Switch to Long-Acting Injectable Cabotegravir + Rilpivirine Every 2 Mos Is Noninferior to Switch to Monthly Injections in Virologically Suppressed Patients at Wk 48

Slideset Download
Conference Coverage
Phase III data demonstrate that long-acting cabotegravir + rilpivirine injections every 2 months is noninferior to monthly injections at Week 48 in virologically suppressed patients with no prior virologic failure.

Released: March 10, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Gilead

Merck & Co., Inc.

ViiV Healthcare